Outcomes According to MSKCC Risk Score with Focus on the
Intermediate-Risk Group in Metastatic Renal Cell Carcinoma
Patients Treated with First-Line Sunitinib: A Retrospective
Analysis of 2390 Patients

J 2020

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

FIALA, Ondrej, Jindrich FINEK, Alexandr POPRACH, Bohuslav MELICHAR, Jindrich KOPECKY et. al.

Basic information

Original name

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Authors

FIALA, Ondrej (203 Czech Republic, guarantor), Jindrich FINEK (203 Czech Republic), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Bohuslav MELICHAR (203 Czech Republic), Jindrich KOPECKY (203 Czech Republic), Milada ZEMANOVA (203 Czech Republic), Katerina KOPECKOVA (203 Czech Republic), Tomas MLCOCH (203 Czech Republic), Tomáš DOLEŽAL (203 Czech Republic, belonging to the institution), Lenka CAPKOVA (203 Czech Republic) and Tomas BUCHLER (203 Czech Republic)

Edition

Cancers, BASEL, MDPI, 2020, 2072-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.639

RIV identification code

RIV/00216224:14110/20:00118607

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/cancers12040808

UT WoS

000535587400038

Keywords in English

renal cell carcinoma; Memorial Sloan-Kettering Cancer Center risk; sunitinib; first line; outcome

Abstract

V originále

Background: The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.

Links

NV19-08-00250, research and development project

Name: Proteotypová klasifikace renálního karcinomu ve vztahu k prognóze a terapeutické odpovědi

Investor: Ministry of Health of the CR

Citovat

FIALA, Ondrej, Jindrich FINEK, Alexandr POPRACH, Bohuslav MELICHAR, Jindrich KOPECKY, Milada ZEMANOVA, Katerina KOPECKOVA, Tomas MLCOCH, Tomáš DOLEŽAL, Lenka CAPKOVA and Tomas BUCHLER. Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. Cancers. BASEL: MDPI, 2020, vol. 12, No 4, p. 1-12. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers12040808.

@article{1670598,
   author = {Fiala, Ondrej and Finek, Jindrich and Poprach, Alexandr and Melichar, Bohuslav and Kopecky, Jindrich and Zemanova, Milada and Kopeckova, Katerina and Mlcoch, Tomas and Doležal, Tomáš and Capkova, Lenka and Buchler, Tomas},
   article_location = {BASEL},
   article_number = {4},
   doi = {http://dx.doi.org/10.3390/cancers12040808},
   keywords = {renal cell carcinoma; Memorial Sloan-Kettering Cancer Center risk; sunitinib; first line; outcome},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients},
   url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/},
   volume = {12},
   year = {2020}
}

TY  - JOUR
ID  - 1670598
AU  - Fiala, Ondrej - Finek, Jindrich - Poprach, Alexandr - Melichar, Bohuslav - Kopecky, Jindrich - Zemanova, Milada - Kopeckova, Katerina - Mlcoch, Tomas - Doležal, Tomáš - Capkova, Lenka - Buchler, Tomas
PY  - 2020
TI  - Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
JF  - Cancers
VL  - 12
IS  - 4
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 20726694
KW  - renal cell carcinoma
KW  - Memorial Sloan-Kettering Cancer Center risk
KW  - sunitinib
KW  - first line
KW  - outcome
UR  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
L2  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
N2  - Background: The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.
ER  -

FIALA, Ondrej, Jindrich FINEK, Alexandr POPRACH, Bohuslav MELICHAR, Jindrich KOPECKY, Milada ZEMANOVA, Katerina KOPECKOVA, Tomas MLCOCH, Tomáš DOLEŽAL, Lenka CAPKOVA and Tomas BUCHLER. Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. \textit{Cancers}. BASEL: MDPI, 2020, vol.~12, No~4, p.~1-12. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers12040808.

Detailed Information on Publication Record